Migraine – Current Treatment – Detailed, Expanded Analysis (EU5)

Prophylactic therapy for migraine is prescribed to reduce the frequency, severity, and duration of migraine attacks and to increase the responsiveness of these attacks to acute treatment. Generic oral AEDs (e.g., topiramate), beta blockers (e.g., propranolol), antidepressants (e.g., amitriptyline), and AbbVie’s Botox are historical mainstays, but an influx of novel CGRP-targeting injectables (Amgen/Novartis’s Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and, more recently in select European markets, Lundbeck’s Vyepti) is transforming the paradigm, with further changes expected following the anticipated entry of oral prophylactic agents in Europe, including Pfizer’s Vydura (Nurtec ODT) and AbbVie’s Qulipta. Although they target a common pathway, these novel agents differ meaningfully in their clinical profile, in addition to their route and frequency of administration; as such, they appeal differentially to patients and the various specialists prescribing prophylactic treatment (e.g., general practitioners / internal medicine physicians [GPs / IMs], neurologists). Understanding prescribing patterns and drivers is paramount for established agents competing for market share and for developers of emerging treatments.


  • How do GP/IMs and neurologists differ in their prescribing for migraine prophylaxis?
  • What patient share do key prophylactic therapies and brands attain in chronic and episodic migraine patients and by line of therapy in migraine patients initiating prophylaxis?
  • What impact will the entry of the oral CGRP-targeted therapies have on the prescribing of anti-CGRP MAbs, and what factors will drive this dynamic?
  • Which anti-CGRP MAbs perform best on key clinical factors? Which are most prescribed, and why?
  • What impact has the emergence of anti-CGRP MAbs had on the prescribing of Botox, and what drives this dynamic?
  • What percentage of patients are treated with monotherapy versus combination therapy? What are the most common combinations?
  • What are physicians’ goals regarding the duration of prophylactic therapy, and at what point do they reevaluate whether to continue treatment?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

launch Related Market Assessment Reports